Develop an oral alternative to injectable GLP-1 drugs for obesity and type 2 diabetes management, potentially enabling more flexible dosing and improved patient adherence.
Phase 3 for obesity and diabetes with cardiovascular and kidney outcome trials.
Updated 9 Jun 2026Checked 11 Oct0 updates this week
Unlike weekly injectables, oral elecoglipron enables different dosing schedules.
Signals the brain to reduce appetite and improve insulin secretion in type 2 diabetes.
Phase 3 trials measure heart and kidney protection beyond weight loss.
| Spec | Elecoglipron |
|---|---|
| 36-week weight loss | 11.8%R (reported) |
| ≥5% weight loss achieved | 88.8%R (reported) |
| HbA1c reduction (diabetes) | 1.9%R (reported) |
R reported by the company
AstraZeneca
Biopharmaceutical, oncology, cell therapy, in vivo CAR-T
AstraZeneca is a biopharmaceutical company developing treatments in oncology, rare disease, and cell therapy. Acquired EsoBiotec in May 2025 for up to $1B to advance in vivo CAR-T therapies.
